These results together indicate that LRRC33 will be a promising drug target for specifically blocking the myeloid-derived TGF-β1 signal in therapeutic applications, such as cancer immunotherapy, just like the GARP-targeted TGF-β1 inhibition for Treg cells46. Here, LRRC32 is linked to cancer.